Efficacy of intravenous nifekalant, a pure Ikr blocker, for atrial tachyarrhythmia with heart failure

S. Takatsuki, H. Mitamura, M. Ieda, O. Kinebuchi, Y. Kurita, M. Hara, S. Ogawa

Research output: Contribution to journalArticle

Abstract

We describe 2 cases of congestive heart failure due to atrial tachyarrhythmias, which were successfully treated by a new Ikr blocker, nifekalant. Case 1 was 59-year old male with congestive heart failure caused by atrial fibrillation with rapid ventricular response due to manifest WPW syndrome. Intravenous administration of nifekalant (0.3mg/kg) successfully slowed ventricular response with reducing the frequency of the pre-excitation. Case 2 was 73-year old male having a history of hypertention, also exhibited heart failure caused by atrial flutter with 2 to 1 or 3 to 1 atrioventricular conduction. The atrial flutter was successfully converted to sinus rhythm with the same dose of intravenous nifekalant. In both cases, the heart failure did not aggravated by the use of nifekalant but recovered soon by treating atrial tachyarrhythmias. Intravenous nifekalant may be a useful option in the management of atrial tachyarrhythmia with heart failure.

Original languageEnglish
Pages (from-to)852-855
Number of pages4
JournalTherapeutic Research
Volume22
Issue number4
Publication statusPublished - 2001 Jan 1

Keywords

  • Artrial fibrillation
  • Atrial flutter
  • Heart failure
  • K channel blocker

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Efficacy of intravenous nifekalant, a pure Ikr blocker, for atrial tachyarrhythmia with heart failure'. Together they form a unique fingerprint.

Cite this